On 9/6/19 Aprea Therapeutics https://www.aprea.com filed the paperwork for its IPO. The company anticipates raising up to $86 million. Aprea has facilities in Boston, MA and Stockholm, Sweden. The company will trade NDADAQ under the symbol, "APRE."
Aprea is focused on the discovery and development of novel anticancer compounds that reactivate the tumor suppressor protein, p53. Its lead candidate, APR-246, is a first-in-class small molecule in clinical development for myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), as well as additional hematologic and solid tumor malignancies.Aprea has commenced a Phase 3 clinical study in p53 mutated MDS and completed enrollment in a Phase 1b/2 clinical trial in p53 mutated high-risk MDS and oligoblastic AML with APR-246 and azacitidine.
In April of 2019, the US FDA granted Fast Track and Orphan Drug Status to APR-246 for the treatment of patients with MDS having a TP53 mutation. The company is also developing second generation p53 reactivators that they believe have best-in-class potential.
The company closed a $55 million Series C round in December of 2018. The round was led by the Redmile Group, with participation by new investor Rock Springs Capital and existing investors 5AM Ventures, Versant Ventures, HealthCap, Sectoral Asset Management and Karolinska Development AB (Nasdaq Stockholm: KDEV).